Apimeds Pharmaceuticals US, Inc. (APUS)
(Delayed Data from AMEX)
$1.79 USD
-0.11 (-5.79%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $1.79 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APUS 1.79 -0.11(-5.79%)
Will APUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APUS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for APUS
50 Day Moving Average Support appears for APUS after 5.94% move
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
APUS falls 2.88% on September 15, leaving the technical picture intact
APUS forms Pocket Pivot on September 12
Is APUS ready to move higher? 20 Day Moving Average Support shows up after declining 3.96%